BiotechTube
Home/Veru/Samuel Fisch
SF

Samuel Fisch

Executive Director, Investor Relations & Corporate Communications

Veru

Therapeutic Areas

Cardiometabolic DiseasesInflammatory Diseases

Veru Pipeline

DrugIndicationPhase
Enobosarm (VERU-024)Preservation of lean muscle mass & augmentation of fat loss in overweight/obese patients on GLP-1 RA therapyPhase 2b
Sabizabulin (VERU-111)Atherosclerotic Coronary Artery DiseasePhase 2 (Planned)

Leadership Team at Veru

MS
Mitchell Steiner, M.D., F.A.C.S.
Chairman, President, and Chief Executive Officer
HF
Harry Fisch, M.D., F.A.C.S.
Vice Chairman, Chief Corporate Officer
MG
Michele Greco
Chief Financial Officer and Chief Administrative Officer
KG
K. Gary Barnette, Ph.D.
Chief Scientific Officer
GB
Gary Bird, Ph.D.
Executive Vice President, Quality and Regulatory Affairs
KG
Kevin Gilbert, JD, CPA
Executive Vice President, Corporate Development
PG
Philip Greenberg
Executive Vice President, General Counsel
DR
Domingo Rodriguez, M.D.
Executive Vice President, Global Clinical Operations
View full Veru profile